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Preclinical and clinical studies for cardiac cell therapy have only seenmoderate success due to poor engraft-
ment and survival of transplanted cells. In this issue ofCell StemCell, Ye et al. (2014) employ a growth-factor-
loaded fibrin patch and show improved cardiovascular cell survival after cell transplantation into a porcine
model of ischemia reperfusion.In recent years stem-cell-based cardiac
therapy has centered on the premise
that functional myocardium may be
restored by transplanting cardiovascu-
lar cells derived from exogenous stem
cells into injured hearts. However, poor
engraftment and survival of the trans-
planted cells, despite the reported benefi-
cial effects, has led to the conclusion that
cell transplantation may activate endoge-
nous repair mechanisms through stem-
cell-mediated paracrine effects rather
than contribute directly to cell replace-
ment (Garbern and Lee, 2013). While in-
terest in transplanting autologous cells
such as bone marrow or mesenchymal
stem cells for cardiac repair has waned
due to their lack of consistent efficacy,
the potential for transplantation of plurip-
otent stem cell (PSC)-derived cardiac
cells to be more efficacious at replacing
damaged myocardium remains to be
demonstrated.
In a proof-of-principle study to address
the effect of transplanting PSC-derived
cardiac cells, Xiong et al. have previ-
ously shown that fibrin-patch-mediated
delivery of human embryonic stem cell
(hESC)-derived endothelial cells (ECs)
and smooth muscle cells (SMCs) into
mouse and swine models of ischemic
myocardial injury significantly restored
cardiac function and structure (Xiong
et al., 2011). hESC-derived ECs and
SMCs recruited endogenous stem cells
into the ischemic injury area, resulting
in reduced native cardiomyocyte (CM)
apoptosis both in vitro and in vivo. Given
the generally low retention of transplanted
cells in this study, the salubrious effects
were attributed at least partly to the para-crine effects of cytokines released by the
transplanted cells.
In this issue of Cell Stem Cell, Ye et al.
have now demonstrated that a cytokine-
loaded patch and transplanted human
induced PSC (hiPSC)-derived trilineage
cells (CMs, ECs, and SMCs) provide syn-
ergistic effects on cardiac function in a
porcine model of ischemia reperfusion
(Ye et al., 2014). Consistent with the re-
sults from their prior study, the engraft-
ment of these trilineage cells was aided
by the introduction of an epicardial
fibrin-based patch. However, they im-
plemented one key additional feature—
insulin-like growth factor 1 (IGF-1) micro-
spheres—in these cell-free patches prior
to transplantation. Remarkably, the pres-
ence of IGF-1 in the patch led to a sub-
sequent increase in CM and vascular cell
engraftment. In aggregate, the combined
effects from the presence of the patch,
the slow release of IGF-1, and the
improved engraftment of hiPSC-derived
ECs, SMCs, and CMs led to significant
improvement in overall cardiac function.
These findings by Ye et al. (2014)
are particularly noteworthy given that
numerous ongoing preclinical and clinical
studies using various cell types and deliv-
ery strategies have only seen moderate
success due to poor engraftment and sur-
vival of the transplanted cells, which in
turn yielded insufficient gain in cardiac
function. To address these challenges,
diverse biomaterial and tissue engineer-
ing technologies have emerged over the
last decade, demonstrating great poten-
tial to augment the efficiency of cardiac
cell therapy (Christman and Lee, 2006;
Ye et al., 2013). Biomaterials can be im-Cell Stem Cell 15,planted as cardiac patches or injected
as hydrogels and applied as an acellular
scaffold or as a delivery vehicle for cells
and/or other therapeutic macromole-
cules. Cardiac patches can be fabricated
from naturally derived biomaterials such
as collagen, Matrigel, fibrin, alginate, de-
cellularized (heart) tissues, and synthetic
polymers such as polyglycolic acid and
polytetrafluoroethylene (Christman and
Lee, 2006; Serpooshan et al., 2013). The
putative mechanisms of benefit from the
epicardial patch include (1) mechanical
support for the damaged tissue and pre-
vention of adverse remodeling; (2) crea-
tion of a biomimetic microenvironment
for cell migration, proliferation, and neo-
vascularization; (3) an enhancement of
the retention of transplanted cells by
prevention of cell ejection after release;
and (4) delivery of cardioprotective
compounds by sustained release into
the injured area.
To explore the potential benefit that a
cardiac patch might provide to enhance
transplanted cell retention and survival,
Zhang and coworkers have previously
explored the introduction of autologous
porcine MSCs, seeded within fibrin
matrices, into swine hearts after experi-
mental myocardial infarction (MI) (Liu
et al., 2004). Moreover, with the availabil-
ity of PSC-derived cardiovascular cells,
they examined the engraftment of hESC-
and hiPSC-derived vascular cells in both
mouse and swine hearts (Xiong et al.,
2011, 2012). In all cases, the fibrin patch
enhanced cell delivery and yielded signif-
icantly greater rates of cell engraftment,
resulting in greater gain in cardiac func-
tion. In their current work, Ye et al. haveDecember 4, 2014 ª2014 Elsevier Inc. 671
Figure 1. Comparison of Cardiovascular Cell Survival with and without a Tissue-Engineered Patch
Schematic diagram of the experiments conducted by Ye et al. (2014) and the reported outcomes from the injection of trilineage cardiac cells derived from hiPSCs
with and without an IGF-1-loaded epicardial fibrin patch.
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loaded fibrin patch onto the epicardial
surface of a swine heart after MI. The
role of this patch was primarily to prevent
leakage of the transplanted cells (hiPSC-
CMs, ECs, and SMCs) through the injec-
tion track and provide a source for IGF-1
cell survival signal, as based on prior
studies. The result from the IGF-1 loaded
patch was quite remarkable: significantly
greater retention and survival of trilineage
cells were achieved (8.97% ± 1.8% in
Cells+Patch and 4.2% ± 1.1% in Cells
Only group at 4 weeks after injection as
opposed to a maximum of 2.6% re-
ported in other studies) (Figure 1). The
current work by Ye et al. (2014) signifi-
cantly extended their prior work by
showing that the presence of trilineage
cells provides a beneficial effect that
goes beyond those achieved by CM
transplantation alone.
As with all groundbreaking studies that
change our basic assumptions, the cur-
rent study raises a number of thought-
provoking questions. For example, is it
the IGF-1 release or the paracrine factors
released by the transplanted cells (or
both) that is improving existing endoge-
nous CM survival in vivo? Also, given the672 Cell Stem Cell 15, December 4, 2014 ª2reported arrhythmia in a prior study
involving hESC-derived CM transplanta-
tion into primate hearts (Chong et al.,
2014), does the absence of arrhythmia
reported here indicate a greater or lesser
degree of cell engraftment or an antiar-
rhythmic effect from the presence of car-
diac patch or IGF-1 release? Furthermore,
the relatively short duration of follow-up
in this study (4 weeks) precludes an
assessment of the long-term function of
these animals after cell transplantation. It
would be important to know whether the
increased CM and vascular cell engraft-
ment can lead to improvement in cardiac
function that goes beyond the duration
seen with their paracrine effects. Addi-
tional studies involving the introduction
of a fibrin patch with IGF-1 with and
without conditioned media obtained
from the trilineage cells but without cell in-
jection may shed light on this question.
In summary, this study by Ye et al.
(2014) address a critical gap in our
knowledge regarding the role of tissue-
engineered patches and their associated
factors in promoting the survival of trans-
planted cardiovascular cells in a large an-
imal model of myocardial injury. The study
highlights the potential mechanisms by014 Elsevier Inc.which the cardiac patch and the engrafted
cardiac cells may contribute to myocar-
dial repair including (1) enhanced cell
retention/survival due to the cytoprotec-
tive effect of the patch and/or the released
IGF-1, (2) improvement of left ventricle
wall stress due to patch integration and
epicardial thickening, (3) enhanced neo-
vascularization in the transplant microen-
vironment via paracrine effects on native
tissue, and (4) improvement in systolic
contractile function through recovery of
host myocardial protein expression. The
progress made here in human cell sur-
vival after transplantation in a preclinical
large animal model of myocardial injury
now takes us one step closer to the use
of PSC-derived cardiovascular cells in
regenerative therapy.REFERENCES
Chong, J.J.H., Yang, X., Don, C.W., Minami, E.,
Liu, Y.-W., Weyers, J.J., Mahoney, W.M., Van
Biber, B., Cook, S.M., Palpant, N.J., et al. (2014).
Nature 510, 273–277.
Christman, K.L., and Lee, R.J. (2006). J. Am. Coll.
Cardiol. 48, 907–913.
Garbern, J.C., and Lee, R.T. (2013). Cell Stem Cell
12, 689–698.
Cell Stem Cell
PreviewsLiu, J., Hu, Q., Wang, Z., Xu, C., Wang, X., Gong,
G., Mansoor, A., Lee, J., Hou, M., Zeng, L., et al.
(2004). Am. J. Physiol. Heart Circ. Physiol. 287,
H501–H511.
Serpooshan, V., Zhao, M., Metzler, S.A., Wei, K.,
Shah, P.B., Wang, A., Mahmoudi, M., Malkovskiy,
A.V., Rajadas, J., Butte, M.J., et al. (2013). Bioma-
terials 34, 9048–9055.Xiong, Q., Hill, K.L., Li, Q., Suntharalingam, P.,
Mansoor, A., Wang, X., Jameel, M.N., Zhang, P.,
Swingen, C., Kaufman, D.S., and Zhang, J.
(2011). Stem Cells 29, 367–375.Xiong, Q., Ye, L., Zhang, P., Lepley, M., Swingen,
C., Zhang, L., Kaufman, D.S., and Zhang, J.
(2012). Circ. Res. 111, 455–468.Cell Stem Cell 15,Ye, L., Zimmermann, W.-H., Garry, D.J., and
Zhang, J. (2013). Circ. Res. 113, 922–932.Ye, L., Chang, Y.-H., Xiong, Q., Zhang, P.,
Zhang, L., Somasundaram, P., Lepley, M.,
Swingen, C., Su, L., Wendel, J.S., et al.
(2014). Cell Stem Cell 15, this issue, 750–761.Pushing the Limits: Defeating Leukemia
Stem Cells by Depleting TelomeraseYa-Huei Kuo1,* and Ravi Bhatia1,*
1Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
*Correspondence: ykuo@coh.org (Y.-H.K.), rbhatia@coh.org (R.B.)
http://dx.doi.org/10.1016/j.stem.2014.11.014
Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical
cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of
Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and
may represent a promising therapeutic approach in AML.Telomeres, the nucleoprotein complexes
with repetitive sequences that cap the
ends of eukaryotic chromosomes, are
essential for maintaining replicative ca-
pacity and genomic stability. The length
of telomeres shortens with each replica-
tion cycle, thereby limiting cellular life
span. Telomere maintenance is particu-
larly important for pluripotent stem cells
(Pucci et al., 2013) and multipotent stem
cells, including hematopoietic stem cells
(Wang et al., 2014), and is critical for
tissue homeostasis or regeneration.
The telomerase complex, composed of
a catalytic subunit telomerase reverse
transcriptase (TERT), a telomerase RNA
component (TERC), and a shelterin scaf-
fold can lengthen telomeric DNA through
a RNA-directed DNA polymerization
mechanism.
Telomere shortening is among the hall-
marks of aging and malignant cells. Once
a telomere is critically short, the chromo-
some ends elicit a double-strand-break-
like DNA damage response that results
in growth arrest and cell death. Age-
adjusted telomere length appears to be
significantly reduced in patients with
acute myeloid leukemia (AML), myelodys-
plastic syndrome (MDS), and chronicmyeloid leukemia (CML) as compared to
matched controls. Telomere shortening
may reflect the increased replication
required for leukemia development, but
it could also result from altered telomere
regulatory mechanisms. Indeed, telo-
merase mutations are associated with
myeloid malignancies, especially MDS
and AML (Townsley et al., 2014). Most
cancers have relatively short telomeres
but high levels of telomerase activity
compared to normal cells. Enhanced
telomerase activity likely represents an
important adaptive mechanism that
allows leukemia cells to continue to
replicate despite marked telomeric short-
ening. Telomerase activity has been
shown to be increased in CML and to be
required for leukemia development (Vice-
nte-Duen˜as et al., 2012). In addition, the
AML-related fusion genes MLL-AF4 and
AML1-ETO have been reported to upre-
gulate TERT expression (Gessner et al.,
2010).
AML originates from small populations
of leukemia stem cells (LSCs) that have
extensive self-renewing capacity but
tend to be resistant to chemotherapy
and contribute to relapse. It can be pre-
dicted that LSCs might be especiallydependent on telomerase activity to sus-
tain long-term replicative capacity and
that inhibition of telomerase activity may
be a potential approach to target LSC
self-renewal. In this issue of Cell Stem
Cell, Bruedigam and colleagues (Bruedi-
gam et al., 2014) examined the role of
telomerase in AML LSC function and
demonstrated an essential role for telo-
merase in the maintenance of functional
LSCs (Figure 1). Using mice depleted of
the RNA component of the telomerase
(Terc/) and a well-defined genetic
model of MLL-AF9-induced AML, they
showed that telomerase deficiency
greatly compromised self-renewal of
LSCs. Although AML developed with full
penetrance, suggesting that telomerase
is not essential for leukemia initiation,
telomerase deficiency greatly reduced
leukemia burden and the frequency of
functional LSCs measured in limiting dilu-
tion and secondary transplantation as-
says. Similar effects were detected using
additional AML models, including the
AML1-ETO/KRASG12C AML and BCR-
ABL/NUP98-HOXA9 AML, suggesting
that the effects of telomerase deficiency
were independent of the oncogenic
driver of AML. These results support anDecember 4, 2014 ª2014 Elsevier Inc. 673
